Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
Jun Gong, Edwin M. Posadas, Neil A. Bhowmick, Hyung L. Kim, Timothy J. Daskivich, Amit Gupta, Howard M. Sandler, Mitchell Kamrava, Zachary S. Zumsteg, Stephen J. Freedland, Robert A. Figlin
Abstract
DNA-damage repair (DDR) pathway mutations can sensitize cancer cells to a class of cancer therapeutics known as PARP inhibitors. Given that DDR alterations can be found in up to one-third of advanced prostate cancers, PARP inhibitors have recently been established in treatment-refractory settings. We provide an updated review of the clinical data supporting the 4 PARP inhibitors that have undergone the most investigation thus far in metastatic castrate-resistant prostate cancer (mCRPC). Two of these agents are currently approved for the treatment of DDR-altered mCRPC. We end with a discussion on integration of approved PARP inhibitors into advanced prostate cancer clinical practice.